| Tap a line for its trend | Currentlast close | FY24Mar 2024 |
|---|
| 69.8 | — | |
| 0.1 | 0.1 | |
| 66.2 | 66.2 | |
| 136 | — | |
| 90.2 | 90.2 | |
| 4.1 | 4.1 | |
| 4.5% | 4.5% | |
| −2.0 | −2.0 | |
| −1.8 | −1.8 | |
| −2.0% | −2.0% | |
| −₹1.74 | −₹1.74 | |
| −14.3 | −14.3 | |
| −10.5 | −10.5 | |
| −24.8 | −24.8 | |
From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.
In ₹ Crore except Per Share 12 Months Ending | FY24 31/03/2024 | Current last close | |
|---|---|---|---|
| Market Capitalization | — | 69.8 | |
| - Cash, Equiv & ST Investments | 0.1 | 0.1 | |
| + Total Debt | 66.2 | 66.2 | |
| Enterprise Value | — | 135.9 | |
| Revenue | 90.2 | 90.2 | |
| EBITDA | 4.1 | 4.1 | |
| Margin % | 4.53 | 4.53 | |
| EBIT | -2.0 | -2.0 | |
| Net Income | -1.8 | -1.8 | |
| Margin % | -1.98 | -1.98 | |
| EPS, Adj (current shares) | -1.74 | -1.74 | |
| Cash from Operations | -14.3 | -14.3 | |
| Capital Expenditures | -10.5 | -10.5 | |
| Free Cash Flow | -24.8 | -24.8 | |
Figures from the company's filings with NSE
In FY24 its consolidated net loss was ₹1.8 crore on revenue of ₹90.2 crore. Its debt-to-equity ratio was 0.89 on 31 March 2024.
No. Sunil Healthcare had borrowings of ₹66.2 crore on 31 March 2024 (consolidated balance sheet), a debt-to-equity ratio of 0.89. Its cash and current investments were ₹3.6 crore, so its net debt was ₹62.6 crore.
Sunil Healthcare's debt-to-equity ratio was 0.89 on 31 March 2024: borrowings of ₹66.2 crore against total equity of ₹74 crore.
Sunil Healthcare's book value per share was ₹72.04 on 31 March 2024: shareholders' equity of ₹74 crore divided by the 1.03 crore shares in issue.
Sunil Healthcare's net worth — shareholders' equity in its consolidated balance sheet — was ₹74 crore on 31 March 2024.
Sunil Healthcare's basic earnings per share (EPS) were −₹1.74 in FY24.
In FY24, Sunil Healthcare generated ₹14.3 crore of cash from operations and spent ₹10.5 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of −₹24.8 crore.
In FY24 (April 2023–March 2024), Sunil Healthcare's consolidated net loss was ₹1.8 crore, on revenue from operations of ₹90.2 crore.
On FY24 consolidated figures, against Kwality Pharmaceuticals: Sunil Healthcare's operating margin of −2.2% is the lower of the two (Kwality Pharmaceuticals 15.3%; peer average 15.3%).
From Sunil Healthcare's own consolidated results, balance sheets and shareholding patterns filed with NSE, and NSE prices (the latest used here: the 29 October 2026 close). Ratios are calculated by Alphave from those filings as each answer describes.
Consolidated figures from the company's filings with NSE; prices are NSE closing prices.
